Wealth Enhancement Advisory Services’s Protagonist Therapeutics PTGX Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$520K	Buy	3,958 +301	+8%	+$31.4K	﹤0.01%	2652
2026 Q1	$380K	Buy	3,657 +103	+3%	+$9.12K	﹤0.01%	2559
2025 Q4	$292K	Buy	3,554 +43	+1%	+$3.52K	﹤0.01%	2943
2025 Q3	$230K	Buy	+3,511	New	+$200K	﹤0.01%	3005

Other funds holding PTGX

MAP

Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return

SOADOR

State of Alaska Department of Revenue Juneau, Alaska $10.1B AUM 42.83% 1-Year Est. Return

LSERS

Louisiana State Employees Retirement System Baton Rouge, Louisiana $5.7B AUM 35.76% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

YCM

Yousif Capital Management Bloomfield Hills, Michigan $8.94B AUM 42.6% 1-Year Est. Return

COPPSERS

Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return

FSA

Franklin Street Advisors Chapel Hill, North Carolina $1.79B AUM 28.1% 1-Year Est. Return

Cache Advisors San Francisco, California $1.18B AUM 44.04% 1-Year Est. Return

CGH

Crossmark Global Holdings Houston, Texas $7.71B AUM 37.66% 1-Year Est. Return

Burney Company Reston, Virginia $3.71B AUM 37.66% 1-Year Est. Return

Wealth Enhancement Advisory Services's PTGX Position: Q2 2026 in Review

Wealth Enhancement Advisory Services increased its Protagonist Therapeutics (PTGX) stake by 8.2% in Q2 2026, buying an estimated $31.4K and bringing the position to 3,958 shares worth $520K. The position accounts for ﹤0.01% of the portfolio, ranked #2652.

Wealth Enhancement Advisory Services first reported a position in PTGX in Q3 2025 and has held it in 4 quarters since. 30 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

Wealth Enhancement Advisory Services held 3,958 shares of Protagonist Therapeutics worth $520K as of Q2 2026.
Wealth Enhancement Advisory Services bought 301 Protagonist Therapeutics shares in Q2 2026, an estimated $31.4K.
Protagonist Therapeutics made up ﹤0.01% of Wealth Enhancement Advisory Services's portfolio in Q2 2026, its #2652 holding.
Wealth Enhancement Advisory Services first reported a position in Protagonist Therapeutics in Q3 2025 and has held it in 4 quarters since.
30 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q2 2026, filed 15 Jul 2026.